Back to News
Market Impact: 0.3
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates
Source: zacks.com
Corporate EarningsHealthcare & BiotechAnalyst Estimates
Aytu BioPharma reported a quarterly loss of $0.05 per share, substantially better than the Zacks consensus forecast for a $0.22 loss. The result also improved from a $0.26 per-share loss in the prior-year quarter, indicating a $0.21 year-over-year reduction in losses.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.48
Ticker Sentiment
AYTU0.72
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FIGS Beats Earnings as Demand Outstrips Supply, CEO Trina Spear Says
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- As tech swoon roils market, US inflation data on tap
- Investing in Prediction Markets Will Pay Off, DraftKings CEO Says